Quick Facts / Company Snapshot
- Company Name: Agilent Technologies, Inc.
- Ticker Symbol: A
- Stock Exchange: New York Stock Exchange
- Year of Incorporation: 1999
- State of Incorporation: Delaware
- Corporate Headquarters: 5301 Stevens Creek Blvd., Santa Clara, California 95051
- Total Net Revenue (2025): $6,948 million
- Net Income (2025): $1,303 million
- Income from Operations (2025): $1,479 million
- Total Assets (2025): $12,727 million
- Total Liabilities (2025): $5,986 million
- Cash and Cash Equivalents (2025): $1,789 million
- Global Employees (2025): Approximately 18,100
- Research and Development Expenses (2025): $455 million
- Highest Revenue Segment: Agilent CrossLab ($2,908 million)
- Highest Revenue Region: Americas ($2,806 million)
- Product Revenue (2025): $4,944 million (71.16% of total revenue)
- Services and Other Revenue (2025): $2,004 million (28.84% of total revenue)
- President and CEO: Padraig McDonnell
- Major 2024 Acquisition: BIOVECTRA (Acquired for $915 million)
Company overview
Agilent Technologies, Inc. operates as a global leader within the life sciences, diagnostics, and applied markets. The enterprise provides comprehensive, application-focused solutions that encompass instruments, software, services, and consumables for the entire laboratory workflow. The organizational focus revolves around enhancing the customer experience, delivering differentiated product solutions, and driving laboratory productivity improvements worldwide.
- The enterprise employs approximately 18,100 people across its global operations as of October 31, 2025.
- Centralized order fulfillment and supply chain operations provide manufacturing, engineering, and strategic sourcing resources.
- A global infrastructure organization supports shared services in finance, information technology, legal, and human resources.
The business reaches its diverse customer base primarily through direct sales channels. To ensure broad market penetration, the enterprise also utilizes distributors, resellers, manufacturers’ representatives, and electronic commerce platforms. A recent corporate reorganization aligned the operational structure to better support a market-focused, customer-centric strategy, dividing the business into three distinct reportable segments.
Business segments
The operations of the enterprise are structured into three distinct reportable business segments. These segments are organized based on the nature of the products and services offered, as well as the specific laboratory workflows they address.
- Agilent CrossLab: Generated $2,908 million in net revenue in 2025, accounting for 41.85% of total net revenue.
- Life Sciences and Diagnostics Markets: Generated $2,726 million in net revenue in 2025, accounting for 39.23% of total net revenue.
- Applied Markets: Generated $1,314 million in net revenue in 2025, accounting for 18.91% of total net revenue.
Agilent CrossLab
The Agilent CrossLab segment delivers an extensive portfolio of services and consumables that spans the entire laboratory ecosystem. This division also encompasses software and laboratory automation solutions designed to improve customer outcomes. The segment represents a broad range of offerings tailored to serve customer needs across various end-markets and specialized applications.
- The segment generated $2,908 million in net revenue and $925 million in operating income during 2025.
- A significant portion of the consumables portfolio is vendor-neutral, allowing the enterprise to supply customers regardless of their instrument choices.
- The segment supports approximately 59,700 customers globally.
Operations within this segment are highly recurring in nature, making them less susceptible to market seasonality and broader industry cycles compared to traditional instrument businesses. The services portfolio includes repairs, parts, maintenance, installations, training, compliance support, software as a service, and asset management. The consumables portfolio features sample preparation products, custom chemistries, and specialized laboratory supplies.
Life Sciences and Diagnostics Markets
The Life Sciences and Diagnostics Markets segment provides active pharmaceutical ingredients, reagents, instruments, software, and consumables. These solutions enable clinical and life sciences researchers to interrogate samples at the cellular and molecular levels. The segment operates across seven primary areas of activity, including liquid chromatography, mass spectrometry, cell analysis, pathology, and genomics.
- The segment generated $2,726 million in net revenue and $536 million in operating income during 2025.
- A specialty contract development and manufacturing organization (CDMO) operates within this segment, producing synthesized oligonucleotides.
- The segment serves approximately 22,200 customers, primarily in the pharmaceutical, biopharmaceutical, and clinical diagnostic markets.
The operational scope includes providing complete workflow solutions for the quality control analysis of nucleic acid samples. Furthermore, the segment collaborates with major pharmaceutical companies to develop new potential tissue pharmacodiagnostics, also known as companion diagnostics. These companion diagnostics are utilized to identify patients most likely to benefit from highly specific, targeted medical therapies.
Applied Markets
The Applied Markets segment focuses on providing application-focused solutions that enable customers to identify, quantify, and analyze the physical and biological properties of diverse substances. The product portfolio includes gas chromatography, mass spectrometry, molecular spectroscopy, and vacuum technologies. This segment also features a unique business that refurbishes and resells certified pre-owned instruments.
- The segment generated $1,314 million in net revenue and $301 million in operating income during 2025.
- The molecular spectroscopy business offers field and laboratory testing solutions for airport security, explosives testing, and food quality.
- The segment supports approximately 17,200 customers across the chemicals, advanced materials, food, environmental, and forensics markets.
Vacuum technologies developed within this segment are utilized to create, control, measure, and test vacuum environments. These products are critical in the semiconductor, battery, and advanced materials development industries. The segment enables customers to perform vital testing, such as measuring volatile and semi-volatile contaminants to assess food safety and water quality.
History and evolution
The enterprise was incorporated in Delaware in May 1999. Since its inception, the organization has evolved into a global leader in laboratory technologies through extensive internal research, strategic restructuring, and targeted acquisitions.
- In November 2024, a major organizational restructuring was announced to create a more market-focused, customer-centric operation.
- The former Diagnostics and Genomics segment merged with specific liquid chromatography divisions to form the Life Sciences and Diagnostics Markets segment.
- Chemistries, supplies, and laboratory automation divisions were realigned into the Agilent CrossLab segment.
Strategic acquisitions have played a crucial role in expanding the technological capabilities and market reach of the enterprise. On September 20, 2024, the enterprise acquired 100 percent of the stock of BIOVECTRA for a total cash consideration of $915 million. This acquisition significantly expanded the contract development and manufacturing organization capabilities, allowing the business to deliver clinical-to-commercial scale production of complex therapeutics.
- The BIOVECTRA acquisition added capabilities in microbial fermentation and highly potent active pharmaceutical ingredients.
- In fiscal year 2023, the enterprise decided to exit the Resolution Bioscience business, leading to a divestiture for $50 million.
- The divestiture required a long-lived asset impairment charge of $270 million prior to the sale.
The enterprise continuously evaluates its product portfolio, engaging in discussions with third parties regarding potential acquisitions, joint ventures, and strategic investments. This dynamic approach to portfolio management ensures the organization remains at the forefront of evolving industry standards and technological advancements within the post-genomic and applied laboratory environments.
Products and services
The enterprise categorizes its revenue generation into two primary streams: Products, and Services and Other. The product portfolio includes sophisticated analytical instrumentation, software, and consumables, while the services portfolio encompasses essential laboratory support, maintenance, and consulting.
- Products: Generated $4,944 million in 2025, representing 71.16% of total net revenue.
- Services and Other: Generated $2,004 million in 2025, representing 28.84% of total net revenue.
Products: Analytical Instruments and Consumables
The product portfolio features highly configurable systems designed for precise chemical and biological analysis. High-performance liquid chromatography and gas chromatography systems are foundational products used to separate and identify molecules within complex mixtures. These systems are frequently paired with mass spectrometers to analyze analytes ranging from residual pesticides in food to large intact proteins in biological research.
- The enterprise is the world’s leading provider of gas chromatographs, offering both laboratory and portable models.
- Spectroscopy instruments include atomic absorption, microwave plasma-atomic emission, and fourier transform infrared spectrometers.
- The consumables product lines include proprietary scientific instrument parts, such as chromatography columns and specialized glassware.
The cell analysis portfolio provides instruments, reagents, and labware for real-time cellular impedance measurements and flow cytometry. The pathology solutions product family targets primary cancer diagnostics through advanced tissue staining platforms. Genomics products include microarrays for comparative genomic hybridization and target enrichment portfolios for next-generation sequencing workflows.
Services and Other: Laboratory Support and Software
The services and other category provides the necessary support framework to ensure the continuous and compliant operation of complex laboratory environments. This includes contract repair, preventative maintenance, compliance services, and specialized relocation services. The enterprise also offers software as a service, asset management, and consulting services tailored to meet the specific application needs of various industries.
- Software and informatics solutions facilitate instrument control, data acquisition, and secure storage of results.
- Enterprise services include a broad portfolio of integrated laboratory management services, such as procurement and scientific services.
- Consulting services are heavily utilized in the companion diagnostics and nucleic acid solutions businesses.
With advances in digital technologies, many support services are now delivered remotely through omni-channel platforms. The OpenLab laboratory software suite acts as a scalable, open platform that allows customers to capture, analyze, and share scientific data across the entire enterprise, driving significant productivity improvements in quality assurance and control environments.
Brand portfolio
The enterprise operates a diverse brand portfolio spanning advanced analytical technologies and specialized software platforms. While specific revenue figures per brand are not explicitly separated from the broader segment data, these brands hold significant positions within their respective markets.
BIOVECTRA
Acquired in late 2024, BIOVECTRA operates as a wholly-owned subsidiary providing specialized contract development and manufacturing services. The brand delivers clinical-to-commercial scale production capabilities, specializing in microbial fermentation, bioreagents, and highly potent active pharmaceutical ingredients.
OpenLab Laboratory Software Suite
The OpenLab brand represents a scalable, open software platform designed for laboratory informatics. It enables customers to securely capture, analyze, and share scientific data throughout the laboratory and across the broader corporate enterprise, facilitating compliance in strictly regulated environments.
Dako, CoverStainer, and Artisan
These brands represent the core of the pathology solutions business. CoverStainer and Artisan product families target primary cancer diagnostics through specialized tissue staining. The Dako Omnis and Autostainer solutions provide advanced tumor typing through immunohistochemistry and in situ hybridization technologies.
Seahorse, xCELLigence, Novocyte, and BioTek
This collection of brands forms the foundation of the cell analysis portfolio. These platform technologies are utilized to understand underlying cellular physiology, metabolic profiles, and cellular interactions in normal and diseased states, aiding in the development of targeted therapeutics.
Geographical presence
The enterprise operates on a global scale, deriving the majority of its revenue from international markets. The operational footprint is strategically distributed across the Americas, Asia Pacific, and Europe to efficiently serve localized customer bases and mitigate regional economic risks.
- Americas: Generated $2,806 million in 2025, accounting for 40.39% of total net revenue.
- Asia Pacific: Generated $2,219 million in 2025, accounting for 31.94% of total net revenue.
- Europe: Generated $1,923 million in 2025, accounting for 27.68% of total net revenue.
Americas
The Americas region represents the largest revenue-generating geography for the enterprise. The region is home to the corporate headquarters in Santa Clara, California, and features a dense concentration of manufacturing, research, and development facilities. The United States serves as a critical hub for the Life Sciences and Diagnostics Markets and Agilent CrossLab segments.
- Manufacturing facilities are located in California, Colorado, Delaware, Iowa, Massachusetts, Rhode Island, Texas, and Vermont.
- The region hosts significant FDA-registered sites, ensuring compliance for clinical and diagnostic product lines.
- A major planned expansion of manufacturing capacity for nucleic acid-based therapeutics is located in Frederick, Colorado.
Operations in the Americas also include significant facilities in Canada. The recent acquisition of BIOVECTRA brought additional Canadian manufacturing assets, further strengthening the supply chain for active pharmaceutical ingredients and complex therapeutic modalities within the region.
Asia Pacific
The Asia Pacific region is a critical growth market and a major center for outsourced manufacturing and supply chain operations. The enterprise leverages lower-cost manufacturing environments while maintaining strict quality control standards. Economic and trade policies, particularly within China, significantly impact the operational dynamics of this region.
- Manufacturing facilities are situated in Australia, China, Japan, Malaysia, and Singapore.
- Most of the enterprise’s centralized accounting and tax processes are located in India and Malaysia.
- Revenue in this region is subject to fluctuations based on local government stimulus programs and complex international trade tariffs.
Europe
Europe serves as a vital market for advanced clinical diagnostics, pharmaceutical research, and environmental testing. The enterprise maintains a robust physical presence across multiple European nations to support direct sales, specialized manufacturing, and comprehensive service delivery.
- Manufacturing facilities are located in Belgium, Denmark, Germany, Italy, the Netherlands, and the United Kingdom.
- Operations within Europe must comply with stringent regulations, including the European Union’s In Vitro Diagnostic Regulation.
- The direct service delivery organization is regionally based and operates extensively throughout the continent.
Profit and loss
The following table summarizes the consolidated statements of operations for the fiscal years ended October 31, 2025, 2024, and 2023.
| Financial Metric (in millions, except per share data) | 2025 | 2024 | 2023 |
| Product net revenue | $4,944 | $4,672 | $5,051 |
| Services and other net revenue | $2,004 | $1,838 | $1,782 |
| Total net revenue | $6,948 | $6,510 | $6,833 |
| Cost of products | $2,237 | $2,024 | $2,428 |
| Cost of services and other | $1,068 | $951 | $940 |
| Total costs | $3,305 | $2,975 | $3,368 |
| Research and development | $455 | $479 | $481 |
| Selling, general and administrative | $1,709 | $1,568 | $1,634 |
| Total costs and expenses | $5,469 | $5,022 | $5,483 |
| Income from operations | $1,479 | $1,488 | $1,350 |
| Interest income | $62 | $80 | $51 |
| Interest expense | $(112) | $(96) | $(95) |
| Other income (expense), net | $6 | $49 | $33 |
| Income before taxes | $1,435 | $1,521 | $1,339 |
| Provision for income taxes | $132 | $232 | $99 |
| Net income | $1,303 | $1,289 | $1,240 |
| Net income per share – Basic | $4.59 | $4.44 | $4.22 |
| Net income per share – Diluted | $4.57 | $4.43 | $4.19 |
Balance sheet
The following table summarizes the consolidated balance sheets as of October 31, 2025, and October 31, 2024.
| Assets, Liabilities, and Equity (in millions) | 2025 | 2024 |
| Cash and cash equivalents | $1,789 | $1,329 |
| Accounts receivable, net | $1,487 | $1,324 |
| Inventory | $1,025 | $972 |
| Other current assets | $293 | $334 |
| Total current assets | $4,594 | $3,959 |
| Property, plant and equipment, net | $2,023 | $1,778 |
| Goodwill | $4,473 | $4,477 |
| Other intangible assets, net | $445 | $547 |
| Long-term investments | $133 | $175 |
| Other assets | $1,059 | $910 |
| Total assets | $12,727 | $11,846 |
| Accounts payable | $570 | $540 |
| Employee compensation and benefits | $443 | $368 |
| Deferred revenue | $624 | $544 |
| Short-term debt | $304 | $45 |
| Other accrued liabilities | $406 | $398 |
| Total current liabilities | $2,347 | $1,895 |
| Long-term debt | $3,050 | $3,345 |
| Retirement and post-retirement benefits | $126 | $130 |
| Other long-term liabilities | $463 | $578 |
| Total liabilities | $5,986 | $5,948 |
| Common stock | $3 | $3 |
| Additional paid-in-capital | $5,575 | $5,450 |
| Retained earnings | $1,389 | $750 |
| Accumulated other comprehensive loss | $(226) | $(305) |
| Total stockholders’ equity | $6,741 | $5,898 |
Cash flow
The following table summarizes the consolidated statements of cash flows for the fiscal years ended October 31, 2025, 2024, and 2023.
| Cash Flow Metric (in millions) | 2025 | 2024 | 2023 |
| Net income | $1,303 | $1,289 | $1,240 |
| Depreciation and amortization | $257 | $288 | $271 |
| Share-based compensation | $128 | $129 | $111 |
| Net cash provided by operating activities | $1,559 | $1,751 | $1,772 |
| Payments to acquire property, plant and equipment | $(407) | $(378) | $(298) |
| Payments to acquire businesses and intangible assets, net | $4 | $(862) | $(51) |
| Net cash used in investing activities | $(394) | $(1,258) | $(310) |
| Payments for repurchase of common stock | $(425) | $(1,150) | $(575) |
| Payment of dividends | $(282) | $(274) | $(265) |
| Proceeds from issuance of long-term debt | $— | $1,197 | $— |
| Repayment of long-term debt | $— | $(600) | $— |
| Net cash used in financing activities | $(715) | $(752) | $(930) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $459 | $(261) | $537 |
Board of directors and leadership team
The executive leadership team directs the global operations, ensuring the enterprise adapts to rapidly changing market conditions and regulatory environments. The Board of Directors oversees corporate governance and strategic direction.
- Padraig McDonnell: Serves as the President and Chief Executive Officer. He assumed this role in May 2024 after serving as Senior Vice President, Chief Operating Officer, and CEO-elect. Previously, he led the Agilent CrossLab Group and holds extensive experience across the enterprise’s commercial operations.
- Adam S. Elinoff: Serves as Senior Vice President, Agilent and Chief Financial Officer. He joined the enterprise in November 2025, bringing significant financial leadership experience from his previous role at Amgen Inc.
- Bret DiMarco: Serves as Senior Vice President, Agilent and Chief Legal Officer and Secretary. He joined in July 2024, providing extensive legal expertise from his past executive roles in the technology sector.
- Rodney Gonsalves: Serves as Vice President, Corporate Controllership and Chief Accounting Officer. He briefly served as the interim Chief Financial Officer in late 2025.
- Meghan Henson: Serves as Senior Vice President, Agilent and Chief Human Resources Officer, guiding the global human capital strategy.
- Jonah Kirkwood: Serves as Senior Vice President, Agilent and Chief Commercial Officer, overseeing the global commercial organization.
- Simon May: Serves as Senior Vice President, Agilent and President, Life Sciences and Diagnostics Markets Group, driving the strategic vision for the life sciences portfolio.
- Angelica A. Reimann: Serves as Senior Vice President, Agilent and President, Agilent CrossLab Group, managing the services and consumables business.
- Mike Zhang: Serves as Senior Vice President, Agilent and President, Applied Markets Group, drawing on over two decades of manufacturing and supply chain leadership within the company.
Subsidiaries, associates, joint ventures
The enterprise operates through a complex network of wholly-owned and majority-owned subsidiaries located across multiple global jurisdictions. These subsidiaries manage localized manufacturing, sales, and administrative functions.
- Agilent Technologies Canada Holding LLC (Canada)
- Agilent Technologies Germany Holding GmbH (Germany)
- Agilent Technologies Italia S.p.A. (Italy)
- Agilent Technologies Luxco LLC (Delaware)
- Agilent Technologies Netherlands B.V. (Netherlands)
- Agilent Technologies Singapore (Global) Pte Ltd. (Singapore)
- Agilent Technologies Singapore (Holdings) Pte. Ltd. (Singapore)
- Agilent Technologies Singapore (International) Pte. Ltd. (Singapore)
- Agilent Technologies Singapore Corporation Pte. Ltd. (Singapore)
- Agilent Technologies World Trade, Inc. (Delaware)
- BioVectra Inc. (Canada)
- Dako Denmark ApS (Denmark)
Other Investments (Including Minority / Portfolio Holdings)
The enterprise actively manages an investment portfolio that includes short-term and long-term equity investments to support future technological partnerships and secure financial returns.
- Non-Marketable Equity Securities: As of October 31, 2025, the enterprise held long-term investments in non-marketable equity securities without readily determinable fair values with a carrying amount of $55 million.
- These investments are primarily equity stock issued by private companies operating within the life sciences and analytical technology sectors.
- Special Funds: The enterprise holds shares in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities, valued utilizing observable inputs from the active market.
Physical properties (offices, plants, factories, etc.)
The global physical footprint of the enterprise is extensive, designed to support heavy manufacturing, localized direct sales, and specialized research and development.
- As of October 31, 2025, the enterprise owned or leased a total of approximately 6.8 million square feet of space worldwide.
- Owned Properties: Comprise approximately 5.3 million square feet.
- Leased Properties: Comprise approximately 1.5 million square feet.
The facilities are categorized by their operational focus. Manufacturing plants, research and development facilities, warehouse, and administrative properties occupy roughly 6.3 million square feet. Sales and support facilities occupy the remaining 0.5 million square feet. The properties are geographically dispersed, with significant long-lived asset concentrations in the United States ($1,643 million), Germany ($322 million), and Canada ($285 million). Major U.S. manufacturing sites include locations in California, Colorado, Delaware, Massachusetts, Texas, and Vermont.
Founders
The enterprise was incorporated in Delaware in May 1999 as a spin-off from Hewlett-Packard Company. It was established as an independent entity to focus exclusively on measurement, analytical, and medical technologies, carrying forward the engineering legacy of its original parent organization.
Parent
The enterprise operates as the ultimate parent company for its global network of subsidiaries. It has no parent company.
Investments and capital expenditure plans
Capital expenditures are aggressively utilized to expand manufacturing capacity, modernize information technology infrastructure, and sustain high levels of research and development.
- Anticipated Capital Expenditures (2026): The enterprise expects to invest approximately $500 million in fiscal year 2026.
- Manufacturing Expansion: A significant portion of future capital expenditures is dedicated to the planned expansion of manufacturing capacity for the production of nucleic acid-based therapeutics in Frederick, Colorado.
- Research and Development Spending: The enterprise invested $455 million in research and development during 2025, representing a continued commitment to developing innovative technologies across software, systems, and solutions.
- Artificial Intelligence Integration: The organization actively explores and invests in the deployment of artificial intelligence and machine learning technologies to optimize internal business operations and enhance product functionality.
Shareholding pattern
The common stock of the enterprise is actively traded on the New York Stock Exchange. The ownership structure reflects a mix of public and institutional investors.
- As of December 10, 2025, there were 15,935 common stockholders of record.
- There were 283,054,377 shares of common stock issued and outstanding as of October 31, 2025.
- The enterprise actively manages its outstanding share count through aggressive, publicly announced share repurchase programs, utilizing billions of dollars to offset dilution from employee equity incentive plans.
Future strategy
The future strategic orientation of the enterprise remains focused on enhancing the customer experience, delivering highly differentiated product solutions, and driving laboratory productivity improvements globally.
- Supply Chain Optimization: The organization is actively pursuing mitigation strategies against global tariff impacts through supply chain optimization and targeted pricing actions to protect operating margins.
- Market Expansion: Management intends to continually expand the enterprise’s position in developing countries and emerging markets, capitalizing on the rising global demand for clinical diagnostics and food safety testing.
- CDMO Growth: The integration of the newly acquired BIOVECTRA business positions the enterprise to capitalize on the rapidly expanding market for complex nucleic acid-based therapeutics and targeted cell and gene therapies.
Key strengths
The organizational resilience of the enterprise is supported by several foundational operational strengths.
- High Recurring Revenue Base: The Agilent CrossLab segment generated $2,908 million in 2025, providing a massive, highly resilient stream of recurring revenue driven by essential laboratory services and consumables that are insulated from capital expenditure cycles.
- Vendor-Neutral Consumables: A significant portion of the consumables portfolio is vendor-neutral, allowing the enterprise to capture revenue from laboratories utilizing competitors’ hardware.
- Deep Diversification: The business is heavily diversified across product lines, end-markets (pharmaceutical, environmental, food, academic), and geographies, mitigating the risk of downturns in any single sector.
- In-House Manufacturing Competence: The organization manufactures highly specialized components, such as its own gas and liquid chromatography columns, ensuring unmatched product quality and supply chain control.
Key challenges and risks
The enterprise navigates a highly complex web of operational, regulatory, and macroeconomic risks inherent to the global life sciences industry.
- Global Tariff Vulnerability: Changes to trade policies and the implementation of massive global tariffs significantly increase manufacturing costs, disrupt supply chains, and exert heavy downward pressure on gross margins.
- Capital Expenditure Reliance: The sale of high-value analytical instruments relies heavily on the capital spending budgets of pharmaceutical customers and government institutions, which are highly sensitive to broader macroeconomic downturns and interest rate fluctuations.
- Regulatory Compliance Burdens: The operations are subject to intense scrutiny by the FDA, the European Union’s In Vitro Diagnostic Regulation, and the Environmental Protection Agency. Failure to comply can result in severe financial penalties, product recalls, and operational shutdowns.
- Cybersecurity Threats: The reliance on centralized, global information technology systems exposes the enterprise to immense risks from ransomware, data breaches, and unauthorized access, threatening the integrity of highly sensitive customer and patient data.
Conclusion and strategic outlook
Agilent Technologies stands as a formidable architectural force within the global analytical and clinical laboratory ecosystem. By successfully pivoting its structural alignment into three highly focused segments, the enterprise has optimized its ability to serve the complex demands of the pharmaceutical, chemical, and diagnostic markets. The strategic acquisition of BIOVECTRA radically enhances its capabilities within the lucrative contract development and manufacturing sector, particularly for advanced nucleic acid therapeutics. While the enterprise faces immediate headwinds from aggressive global tariff policies, sluggish capital expenditure recovery in certain pharmaceutical sub-sectors, and intense competition, its foundation remains exceptionally robust. Backed by a massive, highly profitable recurring revenue stream from its CrossLab division and a relentless commitment to research and development, Agilent is strategically positioned to navigate near-term macroeconomic turbulence while capturing outsized growth in the multiomics, biopharmaceutical, and precision medicine markets well into the future.
FAQ section
What are the primary products and services offered by Agilent Technologies?
The company provides a comprehensive suite of analytical instruments, including gas and liquid chromatographs, mass spectrometers, and cell analysis platforms. It also offers extensive laboratory services, vendor-neutral consumables, and specialized contract manufacturing for active pharmaceutical ingredients.
How much revenue did the company generate in 2025?
The company generated a total net revenue of $6,948 million during the fiscal year ended October 31, 2025.
What are the main business segments of the company?
The operations are divided into three reportable segments: Agilent CrossLab, Life Sciences and Diagnostics Markets, and Applied Markets.
What was the most significant recent acquisition made by the company?
On September 20, 2024, the enterprise acquired BIOVECTRA for $915 million in cash, significantly expanding its contract development and manufacturing capabilities.
How is the company’s revenue distributed geographically?
In 2025, the Americas generated 40.39% of total net revenue, the Asia Pacific region generated 31.94%, and Europe contributed 27.68%.
What major risks affect the company’s profitability?
Key risks include exposure to volatile global trade tariffs, dependence on the capital spending budgets of pharmaceutical and government customers, stringent FDA and global regulatory compliance requirements, and vulnerabilities to sophisticated cybersecurity threats.
Official Site: https://www.agilent.com
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
